Skip to main content

Enhanced tamoxifen bioavailability after oral administration of tamoxifen in rats pretreated with naringin

Archives of Pharmacal Research volume 31, pages 1631–1636 (2008)Cite this article

Abstract

The aim of this study was to investigate the effect of naringin on the bioavailability and pharmacokinetics of tamoxifen and of its metabolite, 4-hydroxytamoxifen in rats. The pharmacokinetic parameters of tamoxifen and 4-hydroxytamoxifen were determined by HPLC after pretreating with naringin (1.5, 7.5, and 15 mg/kg) 30 min before orally administering tamoxifen (10 mg/kg). Compared with the control group (treated with tamoxifen alone), naringin pretreated animals showed significantly (p<0.01) increased areas under the plasma concentration-time curves (AUC) and peak tamoxifen concentrations (Cmax). The absolute bioavailabilities (AB%) of tamoxifen in naringin pretreated animals were enhanced versus control (from 32.8% to 47.1%), and the relative bioavailabilities (RB%) of tamoxifen in the naringin pretreated groups were 2.02–2.88 times higher than that in the control. No significant changes in the terminal half-life (t1/2) or Tmax of tamoxifen were observed in the naringin pretreated groups. The AUCs of 4-hydroxytamoxifen after pretreating naringin were also significantly elevated (p<0.05) versus the control. But metabolite ratios (MR; AUC of 4-hydroxytamoxifen to tamoxifen) were significantly lower. These results suggest that the enhanced bioavailability of tamoxifen in the presence of naringin might be due to the inhibition of CYP3A4 by naringin. If the results of this study are further confirmed by clinical trials, tamoxifen dosages should be adjusted to avoid potential drug interaction when tamoxifen is used clinically in combination with naringin-containing dietary supplements.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  • Bailey, D. G.., Arnold, J. M. O., and Spence, J. D., Grapefruit juice-drug interactions. Br. J. Clin. Pharmacol., 46, 101–110 (1998).

    PubMed  Article  CAS  Google Scholar 

  • Buchanan, C. M., Buchanan, N. L., Edgar, K. J., Little, J. L., Malcolm, M. O., Ruble, K. M., Wacher, V. J., and Wempe, M. F., Pharmacokinetics of tamoxifen after intravenous and oral dosing of tamoxifen-hydroxybutenyl-beta-cyclodextrin formulations. J. Pharm. Sci., in press (2006).

  • Buckley, M. T. and Goa, K. L., Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Clin. Pharmacokin., 37, 451–490 (1989).

    CAS  Google Scholar 

  • Crewe, H. K., Ellis, S. W., Lennard, M. S., and Tucker, G. T., Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol., 53, 171–178 (1997).

    PubMed  Article  CAS  Google Scholar 

  • Daniel, P. C., Gaskell, J., Bishop, H., Campbell, C., and Nicholson, R., Determination of tamoxifen and biologically active metabolites in human breast tumour and plasma. Eur. J. Cancer Clin. Oncol., 17, 1183–1189 (1981).

    PubMed  Article  CAS  Google Scholar 

  • Dixon, R. A. and Steele, C., Flavonoids and isoflavonoids-gold mine for metabolic engineering. Trends Plant Sci., 4, 394–400 (1999).

    PubMed  Article  Google Scholar 

  • Eagling, V. A., Profit, L., and Back, D. J., Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br. J. Clin. Pharmacol., 48, 543–552 (1999).

    PubMed  Article  CAS  Google Scholar 

  • Fornander, T., Hellstrom, A. C., and Moberger, B., Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J. Nat. Cancer Inst., 85, 1850–1855 (1993).

    PubMed  Article  CAS  Google Scholar 

  • Fried, K. M. and Wainer, I. W., Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography. J. Chromatogr. B. Biomed. Appl., 655, 261–268 (1994).

    PubMed  Article  CAS  Google Scholar 

  • Gant, T. W., O’Connor, C. K., Corbitt, R., Thorgeirsson, U., and Thorgeirsson, S. S., In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol. Appl. Pharmacol., 133, 269–276 (1995).

    PubMed  Article  CAS  Google Scholar 

  • Gottesman, M. M. and Pastan, I., Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385–427 (1993).

    PubMed  Article  CAS  Google Scholar 

  • Ho, P. C., Saville, D. J., Coville, P. C., and Wanwimolruk, S., Content of CYP3A4 inhibitors, naringin, naringenin and bergapten in grapefruit and grapefruit juice products. Pharmaceut. Acta. Helv., 74, 379–385 (2000).

    Article  CAS  Google Scholar 

  • Ho, P. C., Saville, D. J., and Wanwimolruk, S., Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J. Pharm. Pharm. Sci., 4, 217–227 (2001).

    PubMed  CAS  Google Scholar 

  • Jacolot, F., Simon, I., Dreano, I., Beaune, P., Riche, C., and Berthou, F., Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol., 41, 1911–1919 (1991).

    PubMed  Article  CAS  Google Scholar 

  • Jaiyesimi, I. A., Buzdar, A. U., Decker, D. A., and Hortobagyi, G. N., Use of tamoxifen for breast cancer: twenty-eight years later. J. Clin. Oncol., 13, 513–529 (1995).

    PubMed  CAS  Google Scholar 

  • Jordan, V. C., Collins, M. M., Rowsby, L., and Prestwich, G., A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol., 75, 305–316 (1977).

    PubMed  Article  CAS  Google Scholar 

  • Kim, D. H., Jung, E. A., Sohng, I. S., Han, J. A., Kim, T. H., and Han, M. J., Intestinal bacterial metabolism of flavonoids and its relation to some biological activities, Arch. Pharm. Res., 21, 17–23 (1998).

    PubMed  CAS  Google Scholar 

  • Mani, C., Gelboin, H. V., Park, S. S., Pearce, R., Parkinson, A., and Kupfer, D., Metabolism of the antimammary cancer antiestrogenic agent tamoxifen, I. Cytochrome P450-catalysed N-demethylation and 4-hydroxylation. Drug Metab. Dispos., 21, 645–656 (1993).

    PubMed  CAS  Google Scholar 

  • Meier, C. R. and Jick, H., Tamoxifen and risk of idiopathic venous thromboembolism. Br. J. Clin. Pharmacol., 45, 608–612 (1998).

    PubMed  Article  CAS  Google Scholar 

  • Nijveldt, R. J., van Nood, E., van Hoorn, D. E. C., Boelens, P. G., van Norren, K., and van Leeuwen, P. A. M., Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr., 74, 418–425 (2001).

    PubMed  CAS  Google Scholar 

  • Powles, T. J., The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet, 340, 1145–1147 (1992).

    PubMed  Article  CAS  Google Scholar 

  • Rao, U. S., Fine, R. L., and Scarborough, G. A., Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem. Pharmacol., 48, 287–292 (1994).

    PubMed  Article  CAS  Google Scholar 

  • Shin, S. C., Choi, J. S., and Li, X., Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int. J. Pharm., 313, 144–149 (2006).

    PubMed  Article  CAS  Google Scholar 

  • Stone, R., NIH fends off critics of tamoxifen study. Science, 258, 734 (1992).

    PubMed  Article  CAS  Google Scholar 

  • Takanaga, H., Ohnishi, A., Matsuo, H., and Sawada, Y., Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol. Pharm. Bull., 21, 1062–1066 (1998).

    PubMed  CAS  Google Scholar 

  • Thiebaut, F., Tsuruo, T., Hamada, H., Cottesman, M. M., Pastan, I., and Willingham, M. C., Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A., 84, 7735–7738 (1987).

    PubMed  Article  CAS  Google Scholar 

  • Wacher, V. H., Silverman, J. A., Zhang, Y., and Benet, L. Z., Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci., 87, 1322–1330 (1998).

    PubMed  Article  CAS  Google Scholar 

  • Watkins, P. B., The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev., 27, 161–170 (1996).

    Article  Google Scholar 

  • Yeum, C. H. and Choi, J. S., Effect of naringin pretreatment on bioavailability of verapamil in rabbits. Arch. Pharm. Res., 29, 102–107 (2006).

    PubMed  Article  CAS  Google Scholar 

  • Zhang, H., Wong, C. W., Coville, P. G., and Wanwimolruk, S., Effect of the grapefruit flavonoid naringin on pharmacokinetics of quinine in rats. Drug Metabol. Drug Interact., 17, 351–363 (2000).

    PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. BK21 Project Team, College of Pharmacy, Chosun University, Gwangju, 501-759, Korea

    Jun-Shik Choi & Keon Wook Kang

  2. College of Pharmacy, Chosun University, Gwangju, 501-759, Republic of Korea

    Keon Wook Kang

Authors
  1. Jun-Shik Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keon Wook Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keon Wook Kang.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Choi, JS., Kang, K.W. Enhanced tamoxifen bioavailability after oral administration of tamoxifen in rats pretreated with naringin. Arch. Pharm. Res. 31, 1631–1636 (2008). https://doi.org/10.1007/s12272-001-2161-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-001-2161-7

Key words

  • Tamoxifen
  • 4-Hydroxytamoxifen
  • Naringin
  • Bioavailability
  • Pharmacokinetics